

Date of Deposition: December 22, 2003

Attorney Docket No: 24852-501 CIP3



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Nicholas G. Bacopoulos *et al.*
SERIAL NUMBER. : 10/650,025 EXAMINER : Not Yet Assigned
FILING DATE : August 26, 2003 ART UNIT : 1614
FOR : METHODS OF TREATING CANCER WITH HDAC INHIBITORS

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

1. Preliminary Amendment (38 pages);
2. Return Postcard


If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (212) 692-6202, New York, New York. All correspondence should now be directed to the new address for Applicant's representative listed below.

Applicants believe that no additional fees are due in connection with this submission. However, the Commissioner is authorized to credit any overpayment or charge any deficiencies to Deposit Account No. 50-0311, Reference No. 24852-501 CIP3. A duplicate copy of this Transmittal Letter is enclosed.

Respectfully submitted,

Dated: December 22, 2003


EV399525954US


Ivor R. Elrifi, Reg. No. 39,529
Flora W. Feng, Reg. No. 51,673
Attorney/Agent for Applicants
c/o MINTZ, LEVIN
Customer Number: 35437
666 Third Avenue-24th Floor
New York, New York 10017
Tel: (212) 935-3000
Fax: (212) 983-3115

Express Mail Label No.: EV399525954US

Date of Deposit: December 22, 2003

Attorney Docket No: 24852-501 CIP3



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Nicholas G. Bacopoulos *et al.*
SERIAL NUMBER. : 10/650,025 **EXAMINER :** Not Yet Assigned
FILING DATE : August 26, 2003 **ART UNIT :** 1614
FOR : **METHODS OF TREATING CANCER WITH HDAC INHIBITORS**

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

PRELIMINARY AMENDMENT

Amendments to the specification begin on page 2 of this paper.

Amendments to the claims are reflected in the listing of claims which begins on page 30 of this paper.

Remarks begin on page 38 of this paper.